[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:primary-peritoneal-cancer":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":312,"states":334},"Primary Peritoneal Cancer",78,72,[8,16,23,29,36,42,49,55,61,67,73,79,86,92,98,104,109,115,121,127,133,139,146,152,158,164,170,176,182,188,195,201,207,212,218,224,230,236,242,248,254,260,266,271,277,283,289,295,301,307],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07322094","CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:23.202838Z","2026-07-19T19:36:05.068641Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06682988","A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine",[20],"Phase 2","2026-08-26T02:16:26.411851Z","2026-07-05T05:32:16.766886Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06843447","A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)",[12],"2026-08-26T02:15:15.642947Z","2026-07-05T05:32:16.697930Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06803680","A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors",[33],"Phase 1","2026-08-26T02:16:46.951087Z","2026-07-05T05:32:16.694406Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07059845","A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer",[20],"2026-08-26T02:15:40.343619Z","2026-06-04T01:30:07.896241Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT07546500","A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression",[46],"Phase 3","2026-08-26T02:16:48.735701Z","2026-05-29T15:36:40.191734Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06639074","Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial",[20],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:29.723942Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06366490","Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer",[33],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:29.471463Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT05538091","Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",[20],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:29.380981Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06580314","Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer",[46],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.331227Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07218809","AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer",[46],"2026-08-26T02:16:23.080181Z","2026-05-05T02:43:29.327362Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":84,"content_modified":85},"NCT06161025","A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[83],"Phase 2\u002FPhase 3","2026-08-26T02:17:18.747857Z","2026-05-05T02:43:29.195828Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT05610735","Combination Therapy for Recurrent Ovarian Cancer",[12],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:29.195795Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT06888921","A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer",[12],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:29.182828Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT05920798","Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[12],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:29.054306Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":102,"content_modified":108},"NCT05231122","Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer",[20],"2026-05-05T02:43:29.046114Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT07214779","Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression",[46],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:28.882083Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT05942300","CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer",[33],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:28.855543Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06890338","A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",[20],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.627515Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT06787612","Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer",[20],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:28.507434Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06483048","MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer",[33],"2026-08-26T02:19:05.360997Z","2026-05-05T02:43:28.503673Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":144,"content_modified":145},"NCT05415709","Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer",[143],"Early Phase 1","2026-08-03T02:06:20.225302Z","2026-05-05T02:43:28.502526Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT06856499","Cirtuvivint\u002FOlaparib in Breast Cancer Susceptibility Gene\u002FHomologous Recombination Deficiency Platinum Resistant Ovarian Cancer",[33],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:28.484898Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT05739981","Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[12],"2026-08-26T02:15:42.447052Z","2026-05-05T02:43:28.399515Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT04590326","A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab",[12],"2026-08-26T02:18:38.865010Z","2026-05-05T02:43:28.360231Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT03878849","Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer",[20],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:28.317727Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT04055649","ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer",[20],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:28.316450Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT06690775","CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.",[20],"2026-08-26T02:19:03.581490Z","2026-05-05T02:43:28.216661Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT05281471","Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant\u002FRefractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",[46],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:28.112777Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":193,"content_modified":194},"NCT06412120","Study Evaluating Safety, Tolerability, and Metabolism of Niraparib",[192],"Phase 4","2026-08-26T02:19:18.331180Z","2026-05-05T02:43:27.997904Z",{"nct_id":196,"title":197,"phases":198,"status":13,"updated_at":199,"content_modified":200},"NCT02637934","Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET\u002FCT",[33],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.812215Z",{"nct_id":202,"title":203,"phases":204,"status":13,"updated_at":205,"content_modified":206},"NCT05659381","Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer",[46],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:27.677486Z",{"nct_id":208,"title":209,"phases":210,"status":13,"updated_at":84,"content_modified":211},"NCT07226427","A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer",[33],"2026-05-05T02:43:27.657949Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT04919629","APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion",[20],"2026-08-26T02:17:52.450442Z","2026-05-05T02:43:27.623918Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT05983276","Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer",[20],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:27.575641Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":228,"content_modified":229},"NCT04575935","Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial",[46],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:27.394966Z",{"nct_id":231,"title":232,"phases":233,"status":13,"updated_at":234,"content_modified":235},"NCT05952453","Newly Diagnosed Stage III\u002FIV Ovarian Cancer, Neoadjuvant Carbo\u002FTaxol\u002FPembro, Maintenance Olaparib\u002FPembro",[20],"2026-08-26T02:17:16.980188Z","2026-05-05T02:43:27.281937Z",{"nct_id":237,"title":238,"phases":239,"status":13,"updated_at":240,"content_modified":241},"NCT04606914","Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[20],"2026-08-26T02:17:32.059863Z","2026-05-05T02:43:27.132670Z",{"nct_id":243,"title":244,"phases":245,"status":13,"updated_at":246,"content_modified":247},"NCT05128825","A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[20],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:26.726187Z",{"nct_id":249,"title":250,"phases":251,"status":13,"updated_at":252,"content_modified":253},"NCT06971744","Autophagy Maintenance (AUTOMAIN)",[20],"2026-08-26T02:15:47.754948Z","2026-05-05T02:35:31.760638Z",{"nct_id":255,"title":256,"phases":257,"status":13,"updated_at":258,"content_modified":259},"NCT06365853","A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression",[20],"2026-08-03T02:14:57.006298Z","2026-04-29T02:57:57.157665Z",{"nct_id":261,"title":262,"phases":263,"status":13,"updated_at":264,"content_modified":265},"NCT06824467","A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022\u002FTroFuse-022\u002FENGOT-ov84\u002FGOG-3103)",[46],"2026-08-26T02:18:14.396999Z","2026-04-29T02:57:57.142207Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":27,"content_modified":270},"NCT07024784","A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies",[20],"2026-04-29T02:57:57.107467Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT07211659","Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients",[33],"2026-08-26T02:18:40.612983Z","2026-04-29T02:57:57.105965Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT05503797","A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",[20],"2026-08-26T02:19:21.761002Z","2026-07-30T01:46:14.464355Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT06792552","A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors",[33],"2026-08-26T02:16:13.426928Z","2026-07-30T01:46:14.431650Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":293,"content_modified":294},"NCT06014502","Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors",[33],"2026-08-26T02:16:28.221034Z","2026-07-19T19:36:05.129130Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT05684965","XTX301 in Patients With Advanced Solid Tumors",[12],"2026-08-26T02:17:30.961790Z","2026-07-05T05:32:16.814936Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT06431594","A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)",[33],"2026-08-26T02:15:38.131683Z","2026-07-05T05:32:16.753991Z",{"nct_id":308,"title":309,"phases":310,"status":13,"updated_at":96,"content_modified":311},"NCT05867251","Study of AVZO-021 in Patients With Advanced Solid Tumors",[12],"2026-05-05T02:43:29.354579Z",[313,317,321,324,328,331],{"biomarker":314,"count":315,"slug":316},"G1\u002FS-Specific Cyclin-E1",5,"g1-s-specific-cyclin-e1",{"biomarker":318,"count":319,"slug":320},"BRCA Gene Family",4,"brca-gene-family",{"biomarker":322,"count":319,"slug":323},"FRα","fr",{"biomarker":325,"count":326,"slug":327},"BRCA1 Gene",3,"brca1-gene",{"biomarker":329,"count":326,"slug":330},"Folate Receptor Alpha","folate-receptor-alpha",{"biomarker":332,"count":326,"slug":333},"TBCE wt Allele","tbce-wt-allele",[335,339,343,347,351,355,358,362,365,369,372,376,379,382,385,389,392,395,399,402,405,409,413,416],{"state":336,"count":337,"slug":338},"Texas",41,"texas",{"state":340,"count":341,"slug":342},"Florida",35,"florida",{"state":344,"count":345,"slug":346},"New York",33,"new-york",{"state":348,"count":349,"slug":350},"Pennsylvania",31,"pennsylvania",{"state":352,"count":353,"slug":354},"California",28,"california",{"state":356,"count":353,"slug":357},"Ohio","ohio",{"state":359,"count":360,"slug":361},"Massachusetts",22,"massachusetts",{"state":363,"count":360,"slug":364},"Virginia","virginia",{"state":366,"count":367,"slug":368},"Minnesota",21,"minnesota",{"state":370,"count":367,"slug":371},"North Carolina","north-carolina",{"state":373,"count":374,"slug":375},"Missouri",17,"missouri",{"state":377,"count":374,"slug":378},"New Jersey","new-jersey",{"state":380,"count":374,"slug":381},"Oregon","oregon",{"state":383,"count":374,"slug":384},"Washington","washington",{"state":386,"count":387,"slug":388},"Illinois",16,"illinois",{"state":390,"count":387,"slug":391},"Michigan","michigan",{"state":393,"count":387,"slug":394},"Tennessee","tennessee",{"state":396,"count":397,"slug":398},"Connecticut",15,"connecticut",{"state":400,"count":397,"slug":401},"Kentucky","kentucky",{"state":403,"count":397,"slug":404},"Oklahoma","oklahoma",{"state":406,"count":407,"slug":408},"Arizona",14,"arizona",{"state":410,"count":411,"slug":412},"Alabama",13,"alabama",{"state":414,"count":411,"slug":415},"Maryland","maryland",{"state":417,"count":418,"slug":419},"Georgia",12,"georgia"]